219 related articles for article (PubMed ID: 28756883)
1. Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China.
Zhang X; Hu J; Hu Y; Huang H; Jin J; Li J; Liu Q; Shao Z; Wang J; Wang Q; Wu D; Huang X
Clin Ther; 2017 Sep; 39(9):1758-1768. PubMed ID: 28756883
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China.
Zhang X; Hu J; Hu Y; Huang H; Jin J; Li J; Liu Q; Shao Z; Wang J; Wang Q; Wu D; Huang X
Med Sci Monit; 2018 Jul; 24():5258-5270. PubMed ID: 30056458
[TBL] [Abstract][Full Text] [Related]
4. Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies.
Deng Q; Lv HR; Lin XM; Zhao MF; Geng L; Li YM
Curr Med Res Opin; 2018 Jul; 34(7):1209-1216. PubMed ID: 28956459
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
7. Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia.
Kiehl MG; Egerer G; Engelhardt M; Gross B
Mycoses; 2015 Feb; 58(2):76-81. PubMed ID: 25590660
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
Vehreschild JJ; Sieniawski M; Reuter S; Arenz D; Reichert D; Maertens J; Böhme A; Silling G; Martino R; Maschmeyer G; Rüping MJ; Ullmann AJ; Cornely OA
Int J Antimicrob Agents; 2009 Nov; 34(5):446-50. PubMed ID: 19700265
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
10. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
12. [Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections].
Lichtenstern C; Pratschke J; Schulz U; Schmoeckel M; Knitsch W; Kaskel P; Krobot KJ; Weigand MA; Winkler M
Anaesthesist; 2010 Dec; 59(12):1083-90. PubMed ID: 21069271
[TBL] [Abstract][Full Text] [Related]
13. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
14. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach.
Ananda-Rajah MR; Cheng A; Morrissey CO; Spelman T; Dooley M; Neville AM; Slavin M
Antimicrob Agents Chemother; 2011 May; 55(5):1953-60. PubMed ID: 21357302
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
[TBL] [Abstract][Full Text] [Related]
16. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
17. [Outcome analysis of caspofungin in combination with voriconazole for treatment of 12 hematologic malignancies cases with invasive fungal infection].
Sun HL; Zhou X; Shen YF
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):558-9. PubMed ID: 22338183
[No Abstract] [Full Text] [Related]
18. A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin.
Doria C; Bodzin AS; Vaccino S; Daskalakis C; Krawitz S; Ramirez CB
Clin Transplant; 2011; 25(4):569-75. PubMed ID: 20662881
[TBL] [Abstract][Full Text] [Related]
19. Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
Wang L; Wang Y; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Front Med; 2019 Jun; 13(3):365-377. PubMed ID: 30604166
[TBL] [Abstract][Full Text] [Related]
20. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]